Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
about
Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancerEarly Prediction and Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy Using Quantitative DCE-MRI.Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapyPathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapyDifferences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.Axillary and internal mammary sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapyTumor RNA disruption predicts survival benefit from breast cancer chemotherapy.DCE-MRI Texture Features for Early Prediction of Breast Cancer Therapy ResponseSurrogate marker analysis in cancer clinical trials through time-to-event mediation techniques.Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial.Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.Neoadjuvant chemotherapy with MRI monitoring for breast cancer.Nomogram predicts survival benefit from preoperative radiotherapy for non-metastatic breast cancer: A SEER-based study.Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer.Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy.Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT.The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry.Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy.Has the time come for genomic tests to guide the use of adjuvant chemotherapy in node-positive breast cancer?Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment.ICG fluorescence imaging as a new tool for optimization of pathological evaluation in breast cancer tumors after neoadjuvant chemotherapy.Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014.Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial.Luminal A Breast Cancer and Molecular Assays: A ReviewPredictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment
P2860
Q28066481-DD184354-F6D3-4245-9C06-701B6E911904Q35947118-C2CE507D-56B7-4092-9B93-CA9623997579Q35981180-4B014A45-1B44-494D-86B2-C053635BB119Q36132338-CB607B32-E2E4-4E17-AADA-F57E78FD51C5Q36157026-7B794A84-EC68-429C-BC84-DEAAA7467534Q36228539-A56978AE-D932-4BFA-B0AE-91592C18482BQ36368001-DE98CF79-0E39-4899-B4DE-0DA104A91F74Q36574920-1D188570-F88F-469A-93DB-D4647F01639FQ37059543-5BDAD185-ED81-4432-9702-FC26813C6180Q37217746-5AE31D35-2A2A-4258-B452-500EF2113665Q37412557-A4D89B6A-5D58-4ADD-9A0E-F9ACD45E9B5BQ37687524-D9CB601E-F7C8-47CF-BD2A-3FE8FB4B9A65Q38407471-2F72687D-78DF-4869-8F51-EB23888F8C10Q38687135-DCAA69EF-63D5-46FD-B28E-6C448DD80E7AQ38829245-E6DC0956-EB16-47AE-BA38-CA9EC4823761Q38981856-AB026657-5379-4D8A-BD2D-75EAC60CF249Q39007492-D888A3CF-6EF6-458F-8F85-0F68AF9EA0A1Q40142806-364561C2-7AB6-403D-A159-E822D0B9AF71Q40168846-1EE7E9F2-952D-44EB-A855-8DC00C020ADDQ40852747-9794934E-AE20-471B-A65B-306EAC511771Q41483585-6E3BB4A1-A22B-4481-8EFF-9B03870C0F5DQ41507039-DD48E04F-5075-4693-8833-0A3FFDE09B67Q41547727-5B61898B-5C71-45D6-A650-EA870E9B015EQ41997321-E6363635-E3CE-4EDD-9518-616CFC7AFC8EQ42633783-018572E4-1FB6-4B99-8655-1286A2A080F8Q47757066-3F9DDD11-A2F6-43AE-9B18-7B357B1D1AA7Q49649617-041BBFAF-D17D-42B0-AA52-F4F4EBD6F369Q50534660-0D05982B-2B6E-4D93-A7CC-91B20143643EQ53487311-CCE133FB-FB6F-4B01-AD88-E35799A8D56AQ54240388-D91340B7-7CFD-4F6C-8136-7B485B3A4A99Q55013294-BF89B86E-41C8-48E2-A283-9D0905325E22Q55130351-FABDF8B0-3A2B-43E7-83EA-F17BC7ECA75DQ55208892-9F4DAAA7-E3A9-4F37-AF19-A99C0E6F56FDQ57113322-71B60EC2-74F1-4B6B-B035-54451D2F2D94Q58739891-80313EA4-B252-4F9B-9A6F-E43E0227B6AF
P2860
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Pathological complete response ...... 0994/BIG 1-00 phase III trial.
@ast
Pathological complete response ...... 0994/BIG 1-00 phase III trial.
@en
type
label
Pathological complete response ...... 0994/BIG 1-00 phase III trial.
@ast
Pathological complete response ...... 0994/BIG 1-00 phase III trial.
@en
prefLabel
Pathological complete response ...... 0994/BIG 1-00 phase III trial.
@ast
Pathological complete response ...... 0994/BIG 1-00 phase III trial.
@en
P2093
P2860
P356
P1433
P1476
Pathological complete response ...... 0994/BIG 1-00 phase III trial.
@en
P2093
C Moldovan
D A Cameron
EORTC 10994/BIG 1-00 Study investigators
G MacGrogan
G Werutsky
H Bonnefoi
P2860
P304
P356
10.1093/ANNONC/MDU118
P577
2014-03-11T00:00:00Z